



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant

Bawendi et al.

Art Unit: 1743

Serial No.

09/160,454

Filed

September 24, 1998

For

DETECTION OF COMPOUNDS AND INTERACTIONS IN

BIOLOGICAL SYSTEMS USING QUANTUM DOTS

Assistant Commissioner for Patents Washington, DC 20231

Sir:

# INFORMATION DISCLOSURE STATEMENT FILED PURSUANT TO THE DUTY OF DISCLOSURE UNDER 37 CFR §§1.56, 1.97 AND 1.98

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, the Applicant requests consideration of this Information Disclosure Statement.

### PART I: Compliance with 37 C.F.R. §1.97

(Select A, B or C below)

A.	[X] This Information Disclosure Statement is being/has been file	:d
	(check 1, 2, 3 and/or 4 below)	

- 1. [] concurrently with the filing of the above-identified application.
- 2. [] within three months of the filing date of the above identified U.S. Patent application.
- 3. [] within three months of the filing date of the entry of the National Stage, as set forth in 37 C.F.R. §1.491, in an International application.
- 4. [X] before the mailing date of the first Office Action on the merits in the above-identified application.

No fee or certification is required.

B. [] This Information Disclosure Statement has been filed more than three months after the filing date of the present application and after the mailing date of this first Office Action, but before the mailing date of either a final action under 37 C.F.R. §1.113 or a Notice of Allowance under 37 C.F.R. §1.311.

(check 1 or 2 below)

- 1. [] The fee of \$240 as set forth in 37 C.F.R. §1.17(p) is enclosed.
- 2. [ ] Applicants hereby certify, as specified in 37 C.F.R. §1.97(e), that (check a or b below)
  - a. [] each item of information contained in this Information Disclosure

    Statement was cited in a communication from a foreign Patent Office in
    a counterpart for this application not more than three months prior to the
    filing of this Statement.
  - b. [] no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign Patent Office in a counterpart for this application or, to the knowledge of the undersigned after making reasonable inquiry, was known to any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of this Statement.
- C. [] This Information Disclosure Statement has been filed after the mailing date of either a Final action under 37 C.F.R. §1.113 or a Notice of Allowance under 37 C.F.R. §1.311 and before payment of an Issue Fee.

(check a or b below)

- 1. Applicants hereby certify, as specified in 37 C.F.R. §1.97(e), that:
  - a. [] each item of information contained in this Information Disclosure

    Statement was cited in a communication from a foreign Patent Office in
    a counterpart for this application not more than three months prior to the
    filing of this Statement.
  - b. [ ] no item of information contained in this Information Disclosure

    Statement was cited in a communication from a foreign Patent Office in

a counterpart for this application or, to the knowledge of the undersigned after making reasonable inquiry, was known to any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of this Statement.

- 2. A Petition requesting consideration of the Information Disclosure Statement is attached.
- 3. The Petition Fee of \$130 as set forth in 37 C.F.R. §1.17(i)(1) is enclosed.

#### PART II - Information Cited

[X] A. Applicants hereby make of record in the above-identified application the reference(s) listed on the attached form PTO-1449 (modified). The order of presentation of the references should not be construed as an indication of the importance of the references.

# [] PART III: Explanation of Non-English Language References and Remarks Concerning Other Information Cited

The following is a concise explanation of the relevance of each non-English language reference listed on the attached form PTO-1449 (modified):

The following are remarks concerning the other information cited:

#### PART IV: Remarks

Copies of the U.S. and foreign patent(s) and publication(s) indicated on the attached form PTO-1449 (modified) are enclosed. It is respectfully requested that:

- 1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
- 2. The enclosed form PTO-1449 be signed by the Examiner to evidence that the cited patent(s) and publication(s) has (have) been fully considered by the Patent and Trademark Office during the examination of this application;
- 3. The citations for the patent(s) and publication(s) be printed on any patent which issues from this application.

By submitting this Information Disclosure Statement, Applicants make no representation that a search has been performed, of the extent of any search performed, or that more material information may not exist.

By submitting this Information Disclosure Statement, Applicants make no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

By submitting this Information Disclosure Statement, Applicants make no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by Applicants, the Examiner is urged to form his or her own conclusions regarding the relevance of the cited reference(s).

An early and favorable action is hereby requested.

Respectfully submitted,

Elizabeth E. Nugent Reg. No. P43 839

CHOATE, HALL & STEWART Exchange Place 53 State Street Boston, Massachusetts 02109 (617) 248-5000

Dated: January 25, 1999

DS1.458933.1

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner For Patents, Washington, D.C. 20231

4